Inozyme Pharma Inc. (INZY)
Inozyme Pharma Statistics
Share Statistics
Inozyme Pharma has 64.24M shares outstanding. The number of shares has increased by 3.86% in one year.
| Shares Outstanding | 64.24M |
| Shares Change (YoY) | 3.86% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 82.8% |
| Shares Floating | 43.56M |
| Failed to Deliver (FTD) Shares | 1.3K |
| FTD / Avg. Volume | 0.18% |
Short Selling Information
The latest short interest is 3.85M, so 6% of the outstanding shares have been sold short.
| Short Interest | 3.85M |
| Short % of Shares Out | 6% |
| Short % of Float | 8.76% |
| Short Ratio (days to cover) | 5.41 |
Valuation Ratios
The PE ratio is -1.71 and the forward PE ratio is -1.01. Inozyme Pharma's PEG ratio is -0.09.
| PE Ratio | -1.71 |
| Forward PE | -1.01 |
| PS Ratio | 0 |
| Forward PS | 0.3 |
| PB Ratio | 3.01 |
| P/FCF Ratio | -1.89 |
| PEG Ratio | -0.09 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Inozyme Pharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.56, with a Debt / Equity ratio of 0.27.
| Current Ratio | 3.56 |
| Quick Ratio | 3.56 |
| Debt / Equity | 0.27 |
| Debt / EBITDA | -0.15 |
| Debt / FCF | -0.17 |
| Interest Coverage | 18.72 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.52M |
| Employee Count | 67 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -87.45% in the last 52 weeks. The beta is 1.31, so Inozyme Pharma's price volatility has been higher than the market average.
| Beta | 1.31 |
| 52-Week Price Change | -87.45% |
| 50-Day Moving Average | 1.21 |
| 200-Day Moving Average | 3.55 |
| Relative Strength Index (RSI) | 29.85 |
| Average Volume (20 Days) | 711.41K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -104.03M |
| Net Income | -102.02M |
| EBITDA | -104.03M |
| EBIT | -107.58M |
| Earnings Per Share (EPS) | -1.62 |
Balance Sheet
The company has 21.08M in cash and 15.41M in debt, giving a net cash position of 5.67M.
| Cash & Cash Equivalents | 21.08M |
| Total Debt | 15.41M |
| Net Cash | 5.67M |
| Retained Earnings | -387.95M |
| Total Assets | 123.18M |
| Working Capital | 86.78M |
Cash Flow
In the last 12 months, operating cash flow was -91.91M and capital expenditures -62K, giving a free cash flow of -91.97M.
| Operating Cash Flow | -91.91M |
| Capital Expenditures | -62K |
| Free Cash Flow | -91.97M |
| FCF Per Share | -1.46 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
INZY does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for INZY is $15, which is 1624.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $15 |
| Price Target Difference | 1624.1% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
Scores
| Altman Z-Score | -5.64 |
| Piotroski F-Score | 2 |